Insulet reports year-over-year growth

ACTON, Mass. - Insulet Corp. reported revenue of $738.2 million for 2019, a 31% increase compared to 2018.

The company reported full-year revenue of $673.5 million for the Omnipod, broken down by U.S. revenue of $420.2 million and international revenue of $253.1 million, a 30% and 47% increase, respectively.

Insulet reported revenue of $209.4 million for the fourth quarter of 2019, a 27% increase compared to the same period in 2018. Operating income was $18.2 million.

"2019 was a remarkable year for Insulet, marked by disciplined execution of our strategy that allowed us to deliver consistent financial outperformance and strong operational results," said Shacey Petrovic, president and CEO. "With a solid foundation, pipeline of innovative technologies and proven strategy firmly in place, we made progress investing across our global organization to drive sustainable, long-term growth.”

Earlier this month, Insulet and DexCom announced they have partnered to combine current and future Dexcom CGMs with Insulet's tubeless insulin delivery Pod into the Omnipod Horizon System.